Business


Disruptive approaches to accelerate drug discovery and development


part 1: tools, technologies and the core model


Tesla intends to implement and practise an ‘open source’ philosophy to its large patent portfolio and claims it would not pursue any legal action against anyone using them in good faith. This is a hard pill to swallow for the industry at-large. But, the pharmaceutical industry ought to seriously consider such an inclusive strategy to enhance the pace of drug discovery and development for the benefit of humanity’s welfare.


T


he staggering failure rate of experimental drugs in clinical trials indicates that despite huge investments in novel tech-


nologies, productivity gains in the pharmaceutical industry remain elusive. The pharmaceutical industry is facing a serious innovation deficit. The current biopharma model is therefore unsustain- able and disruptive approaches are needed to rem- edy the status quo. It is incumbent upon the biomedical research community to harness the collective intelligence of pharma, biotech, academia, governmental agencies, non-profit research foundations and patient advocacy groups to accelerate innovation. Disruption – the force that both fuels and rises out of innovation – con- tinues to affect every industry on the planet, from financial services to healthcare to telecommunica- tions. For example, consider the recent break- through innovation models: Uber, the world’s largest taxi company owns no vehicles; Facebook, the world’s most popular media owner creates no


Drug Discovery World Spring 2018


content; Alibaba, the world’s most valuable retail- er owns no inventory; and Airbnb, the world’s largest hotelier, owns no real estate. Most recently, three large US corporations, Amazon, Berkshire Hathaway and JPMorgan Chase, have announced the formation of an independent healthcare com- pany for their employees in the United States to deal with the soaring cost of health insurance pre- miums and pharmaceuticals. In ‘The Evolution of


By Ibis Sánchez- Serrano, Dr Tom Pfeifer and Dr Rathnam Chaguturu


“Tesla Motors was created to accelerate the advent of sustainable transport. If we clear a path to the creation of compelling electric vehicles, but then lay intellectual property landmines behind us to inhibit others, we are acting in a manner contrary to that goal.”


Elon Musk, CEO and Chief Architect of Tesla Motors 39


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72